Understanding a Hodgkin lymphoma report: pathology, stage, and Deauville score

A Hodgkin lymphoma file usually contains several different kinds of report: pathology, PET/CT, laboratory results, and a clinician's staging assessment. They answer different questions. Pathology identifies the disease, imaging describes its distribution, and laboratory tests provide information about health and treatment effects. The treatment decision brings those findings together. Reading only words such as “positive,” “stage IV,” or “residual” can turn an uncertain observation into a conclusion that the report does not actually make.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Classical Hodgkin lymphoma may be described as nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted. These terms describe microscopic patterns. They do not independently specify a number of chemotherapy cycles. Stage, disease burden, symptoms, fitness, and response are also central to treatment selection. [S1]
Inflammation, infection, healing, and treatment-related reactions can increase uptake. Checkpoint therapy adds further interpretive considerations. However, it is equally inappropriate to dismiss every new finding as pseudoprogression. Symptoms, examination, the pattern on serial studies, and sometimes tissue sampling help distinguish possible explanations. If the finding would trigger a major salvage-treatment decision, the team may seek specialist image review or a biopsy first. [S2][S7]
Create a one-page list with the final pathology name and remaining uncertainty, evidence supporting the stage, the risk framework, the PET assessment time point and threshold, and the decision that follows. Leave space for the clinician's explanation and the next action. For children or adolescents, also record the age-appropriate protocol being used; adult interpretation rules should not be copied without checking. [S29]

Quick answer

Full guide

Start by checking the patient details, specimen site, examination date, and whether the investigation was performed before or after treatment. There may be pathology addenda and several scans with revised interpretations. Arrange them chronologically and keep the complete pages. A later document does not necessarily repeat every important statement from an earlier one.

The disease name has practical consequences

Classical Hodgkin lymphoma may be described as nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted. These terms describe microscopic patterns. They do not independently specify a number of chemotherapy cycles. Stage, disease burden, symptoms, fitness, and response are also central to treatment selection. [S1]

Nodular lymphocyte-predominant disease has different biological and clinical features; some classifications call it nodular lymphocyte-predominant B-cell lymphoma. It is not the same as lymphocyte-rich classical Hodgkin lymphoma. If one report uses NLPHL or NLPBCL while another says cHL, ask whether the difference reflects a diagnostic disagreement, a classification change, or an error in translation. It should not be dismissed as a harmless abbreviation. [S2]

Phrases such as “gray zone,” “cannot exclude large B-cell lymphoma,” or “differential includes anaplastic large cell lymphoma” may indicate that the treatment-defining diagnosis remains unresolved. An expert review of the specimen may then be more useful than an immediate discussion of a preferred drug. A single compatible stain should not overrule an incomplete diagnostic conclusion.

Reed–Sternberg cells and immunostains belong together

Hodgkin and Reed–Sternberg cells are important pathological clues in classical disease, but similar large cells can occur in other settings. The pathologist interprets their appearance, the background tissue, and the staining pattern as a whole. Patients are not expected to identify these cells from a microscope photograph or independently confirm the diagnosis from an image. [S2]

Markers such as CD30, CD15, PAX5, CD20, and EBER serve different purposes. CD30 positivity alone is not specific for classical Hodgkin lymphoma. CD20 expression does not automatically mean that a common B-cell lymphoma regimen is appropriate. EBER evaluates Epstein–Barr virus-related information in the tissue; it is not, by itself, a diagnosis of an ordinary acute infection needing a separate antiviral prescription.

The proportion of positive cells, staining intensity, and focal or diffuse pattern can influence interpretation, but they cannot be added together into a patient-generated severity score. A Ki-67 percentage likewise cannot predict an individual's lifespan or establish a need for transplantation. A useful question is whether the overall findings securely support the stated diagnosis and whether any missing study could change treatment.

Stage describes distribution

Hodgkin staging considers the number and location of involved lymphatic regions, distribution above and below the diaphragm, and relevant extranodal organ involvement. Stage IV should not be interpreted using the assumptions applied to every advanced solid tumor. Classical Hodgkin lymphoma with advanced distribution may still be treated with curative intent. The stage is one component of the discussion, rather than a personal forecast. [S1]

Imaging language often preserves uncertainty: “possible involvement,” “likely inflammatory,” or “indeterminate.” The treating clinician establishes the overall stage using the available evidence. Not every metabolically active spot should automatically be counted as lymphoma. Additional imaging or a targeted biopsy can sometimes clarify a finding that would change the treatment category, but the value of that investigation depends on the decision it would affect.

A, B, and bulky disease add context

B symptoms have formal definitions involving unexplained fever, substantial night sweats, and unintentional weight loss. A brief low-grade temperature, ordinary perspiration in a warm room, or weight loss from dieting should not be self-classified as a B symptom. An A designation means that qualifying B symptoms were not recorded; it does not mean that fatigue, itching, or other troublesome symptoms are absent. [S8]

“Bulky” refers to a large disease mass, but size or chest-ratio definitions vary between frameworks. Early favorable and unfavorable categories also depend on the criteria being used. Two centers may use different labels because their risk systems differ. Ask which original measurements and risk definition were used, and whether the difference changes the actual proposed treatment. Comparing how alarming the labels sound is less informative. [S23]

A Deauville score is not another stage

PET response assessment often uses the five-point Deauville scale, comparing lesion uptake with reference areas such as the mediastinum and liver. It describes metabolic response rather than creating a “stage V.” Its meaning depends on the timing of the scan, the starting regimen, and the treatment pathway that uses the result. A baseline scan and an end-of-treatment scan do not serve identical purposes. [S28]

A score of 3 is a common source of confusion. Some pathways include it within a negative or complete metabolic response category, while a particular de-escalation strategy may require a stricter threshold. Ask, “Under my regimen, what does this score change?” The answer is more useful than asking whether 3 is universally good or bad. Evidence from a PET-adapted advanced-disease program cannot automatically determine whether an early-stage patient should omit radiation. [S5][S25]

PET activity does not always mean viable lymphoma

Inflammation, infection, healing, and treatment-related reactions can increase uptake. Checkpoint therapy adds further interpretive considerations. However, it is equally inappropriate to dismiss every new finding as pseudoprogression. Symptoms, examination, the pattern on serial studies, and sometimes tissue sampling help distinguish possible explanations. If the finding would trigger a major salvage-treatment decision, the team may seek specialist image review or a biopsy first. [S2][S7]

Technical and timing information matters. Tell the nuclear medicine team about recent treatment, growth-factor injections, vaccination, infection, and factors affecting glucose control. Original DICOM files let a second center examine the lesions and reference tissues directly. Repeating an SUV number from memory or sending several photographed images cannot provide the same basis for review.

Residual size and residual activity are different observations

A mediastinal mass may leave fibrosis or scar tissue after successful treatment, so it does not have to disappear entirely on CT to show a favorable metabolic response. Conversely, shrinkage alone cannot prove that no active disease remains. Anatomical measurements and PET activity complement each other and should be interpreted against the baseline pattern and the full treatment course. [S1]

Terms such as partial response, complete metabolic response, stable disease, and progression may appear in a formal response assessment or within a radiologist's descriptive impression. Clarify which is being reported. If the clinician's explanation differs from the wording on the scan, ask what accounts for the difference, such as a lesion judged to be inflammatory or a protocol-specific threshold. That clarification is more useful than assuming one professional must have made a mistake.

Laboratory values are not a standalone relapse detector

Blood counts, inflammatory markers, and liver or kidney tests can change because of lymphoma, infection, medicines, or unrelated conditions. A single abnormal result does not prove relapse, and normal results cannot exclude every recurrence. To assess a trend, check the units, laboratory reference range, dates, and treatment being given at the time. Values from different laboratories may not be directly comparable without context. [S13]

During checkpoint treatment, thyroid or liver abnormalities may require investigation for immune toxicity. That assessment is separate from determining whether the tumor has responded. Do not ignore abnormal laboratory results because a mass has shrunk, and do not self-prescribe supplements to “normalize” them. The treatment team should explain the likely causes, planned repeat testing, and circumstances that require a drug hold or further specialist care. [S7]

Drug names in an opinion need an indication

A consultation may list ABVD, nivolumab-AVD, brentuximab vedotin-AVD, or other possible routes. Each should be attached to a setting such as early disease, advanced untreated disease, or relapse. The FDA's March 2026 nivolumab-AVD approval specifies previously untreated stage III or IV classical Hodgkin lymphoma and an age boundary. It should not be expanded in a translated report to mean all forms and stages of Hodgkin lymphoma. Local Chinese indications and prescribing arrangements require their own verification. [S3]

The Chinese 2025 official guidance lists several PD-1 medicines for classical Hodgkin lymphoma after defined previous systemic treatment. If an opinion proposes a different setting, it should explain whether this is within the current Chinese label, another evidence-supported clinical choice, or a study. This distinction helps the patient understand consent, payment, and scheduling. Whether a drug is domestically manufactured does not answer those questions. [S7]

Make the report useful at the next visit

Create a one-page list with the final pathology name and remaining uncertainty, evidence supporting the stage, the risk framework, the PET assessment time point and threshold, and the decision that follows. Leave space for the clinician's explanation and the next action. For children or adolescents, also record the age-appropriate protocol being used; adult interpretation rules should not be copied without checking. [S29]

For a second opinion, retain all original text and addenda. Translation must preserve “suspected,” “favored,” and “cannot exclude.” These phrases identify unanswered questions and should not be removed to make the document seem more definite. Do not independently convert an uncertain diagnosis or response state into a confirmed statement for insurance or travel paperwork.

Ask the doctor to summarize the current position in an ordinary sentence: what disease has been confirmed, how secure the stage is, and which result will guide the next decision. Keep the detailed reports, but use that explanation to organize the immediate tasks. Understanding a report is most helpful when it connects the findings to a clear next step.